Neurotensin (trifluoroacetate salt)
目录号 : GC44387
A neuropeptide with diverse biological activities
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >95.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Neurotensin is a neuropeptide that is distributed throughout the CNS and in enteroendocrine cells of the small intestine that has diverse biological activities. In vivo, neurotensin (10-50 μg per hour, i.c.v.) induces hypothermia in rats. Neurotensin signaling is increased and induces analgesia in wild-type mice, and neurotensin knockout mice are defective in basal nociceptive and stress-induced analgesic responses in a cold water swim stress test. It acts as an indirect dopamine antagonist that inhibits dopamine-induced effects at pre- and postsynaptic dopamine receptors. Neurotensin inhibits small bowel motility and secretion of gastric acid, stimulates pancreatic and biliary secretion, increases fatty acid absorption, and stimulates growth of the stomach, colon, pancreas, and small bowel in rats. It also increases growth of breast, pancreatic, and hepatocellular carcinoma cells via induction of IL-8 secretion and activation of epithelial mesenchymal transition (EMT) in vitro and in vivo.
| Cas No. | SDF | ||
| 分子式 | C78H121N21O20•XCF3COOH | 分子量 | 1672.9 |
| 溶解度 | Water: 1 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.5978 mL | 2.9888 mL | 5.9776 mL |
| 5 mM | 0.1196 mL | 0.5978 mL | 1.1955 mL |
| 10 mM | 0.0598 mL | 0.2989 mL | 0.5978 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Peptide characterization with a sulfoethyl aspartamide column
J Chromatogr 1988 Jun 29;443:63-71.PMID:2844842DOI:10.1016/s0021-9673(00)94783-6.
A strong cation-exchange (SCX) high-performance liquid chromatography column (sulfoethyl aspartamide, 200 x 4.6 mm) was used to analyze more than 50 peptides, ranging in length from 5 to 20 residues. These data show that the elution positions of the peptides increase monotonically with the number of positively charged residues. [A 60-min linear gradient of 0 to 100% eluent B at 1 ml/min was used, where eluent A is 5 mM phosphate (pH 3.0)-acetonitrile (75:25) and eluent B is eluent A + 0.5 M sodium chloride.] A comparison of SCX with a standard C18 reversed-phase (RP) column [60-min linear gradient of 0 to 60% B at 1 ml/min, where eluent A is 0.1% trifluoroacetic acid (TFA), and eluent B is 0.095% TFA-acetonitrile (10:90)] further demonstrates the utility of SCX in peptide characterization. SCX separated an (Arg)3-containing peptide from the Arg-deleted peptide while RP could not. In addition, SCX and RP resolved the methionine oxidation products of ACTH (4-10) (RP: Met [O] less than Met [O2] less than Met; SCX; Met [O] less than Met less than Met [O2]), suggesting a mixed-mode mechanism for the ion-exchange system. Finally, SCX separated the sulfated and non-sulfated forms of cholecystokinin (26-33) and Leu-enkephalin as well as the N-terminal acetylated forms of Neurotensin (8-13) and angiotensinogen (1-14) from the respective unmodified peptides.
High-performance liquid chromatography of neuropeptides using radially compressed polythene cartridges
J Chromatogr 1984 Mar 9;306:99-108.PMID:6325486DOI:10.1016/s0378-4347(00)80873-7.
This study was designed to assess practically the suitability of different C18 reversed-phase radially compressed polythene cartridges (Radial-Pak, Waters Assoc.) in two types of radial-compression systems, for the separation and analysis of various neuropeptides at both high (less than 5 micrograms) and low (greater than 100 pg) levels in biological extracts and to compare them with well established techniques using stainless-steel columns. A solvent system fully compatible with both radially compressed and steel columns is described. The completely volatile mobile phase (acetonitrile gradient containing trifluoroacetic acid) allows ultraviolet detection below 215 nm, gives good resolution and is readily compatible with the further radioimmunoassay and bioassay of collected fractions. The efficiency of radially compressed 5 and 10 microns "capped" and "non-capped" C18 silica supports and slurry-packed steel columns has been assessed by: (1) separation and recovery of a complex standard mixture of neuropeptides; (2) separation and subsequent identification of degradation products formed during the incubation of Neurotensin with rat cortical synaptosomes; (3) analysis of alpha-melanotropin and corticotropin-(18-39) in tissue culture media containing varying amounts of foetal calf serum; and (4) characterization of corticotropin-like immunoreactivity in human cerebrospinal fluid. The Z-module fitted with the capped 10-microns irregular C18 silica cartridge gave better resolution than with the mu Bondapak steel column but the selective retention was similar. The back-pressures in the Z-module are much reduced (approximately 13 bar at 1 ml/min); therefore, flow-rates may be increased and analysis times greatly reduced. In order to obtain good resolution with the RCM-100 module which uses a non-capped stationary phase, a salt must be added (e.g. 15 mM sodium chloride) to the mobile phase to reduce polar interactions between the peptide and the free silanol groups on the stationary phase. This makes the solvent non-volatile and therefore less useful.